Keep up to date with every new upload!

Join free & follow Benzinga Strategies
Share
  • 7 years ago
Rodman and Renshaw's Benjamin on the DNDN earnings debacle

Rodman and Renshaw's Benjamin on the DNDN earnings debacle

Rodman and Renshaw senior biotech analyst Dr. Reni Benjamin discusses the causes behind the more than 60% wipeout in Dendreon's market value after their earnings report and how he is tweaking his models going forward.

Comments